AbbVie has completed its acquisition of all outstanding shares of Cerevel Therapeutics in an $8.7bn deal.
In December 2023, the companies signed a definitive agreement under which AbbVie agreed to acquire Cerevel for $45 per share in cash.
Go deeper with GlobalData
Cerevel focuses on creating therapies to treat neurological and psychiatric disorders.
Through this acquisition, AbbVie will bolster its neuroscience portfolio by adding complementary assets from Cerevel’s pipeline.
AbbVie CEO Robert Michael stated: “AbbVie’s acquisition of Cerevel strengthens our foundation in neuroscience and positions us to deliver sustainable long-term performance into the next decade and beyond.
“Our new Cerevel colleagues share our commitment to deliver meaningful change for patients living with neurological and psychiatric conditions. We are excited to welcome the talented Cerevel team to AbbVie.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataCerevel’s pipeline products are aimed at neurological and psychiatric conditions such as Parkinson’s disease, schizophrenia and mood disorders.
Emraclidine is an antipsychotic treatment for schizophrenia from Cerevel.
This asset operates as a positive allosteric modulator of the muscarinic M4 receptor. It has shown encouraging results in a Phase I study and is nearing the completion of two Phase II trials intended to support registration.
Another key asset in Cerevel’s portfolio is tavapadon, a dopamine D1/D5 selective partial agonist for Parkinson’s disease.
Currently in Phase III studies, tavapadon has demonstrated potential as both monotherapy and adjunctive treatment.
A Phase III trial met its primary endpoint, with additional data from ongoing trials expected in the second half of 2024. The acquisition also brings CVL-354, a kappa opioid receptor antagonist targeting major depressive disorder, now in Phase I, and darigabat, an alpha 2/3/5 selective GABAA [γ-aminobutyric acid type A – an inhibitory neurotransmitter] receptor PAM for treatment-resistant epilepsy and panic disorder, currently in Phase II, into AbbVie’s neuroscience pipeline.
